An Early Phase 1 interventional study of Xulin Jiangu granules and Calcitriol capsules in Postmenopausal Osteoporoses, sponsored by Fujian Academy of Traditional Chinese Medicine. Status unknown at 1 site in China. Open to female participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-26.
Sponsored by Fujian Academy of Traditional Chinese Medicine · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Osteoporosis, Postmenopausal with a site in China — 1 open to participants now, 1 under way, none of them phase 3. Osteoporosis, Postmenopausal · China.
Among the 25 studies in Osteoporosis, Postmenopausal with a site in China, this one is the 17th largest by planned enrollment of the 21 interventional ones that give a count, is one of 6 that started in 2019, is one of 5 in phase 1, and was the 10th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 25 studies in Osteoporosis, Postmenopausal with a site in China is open now. Recruiting first, the newest first:
Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Sites in China
Ages 50+ · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 50 Years to 70 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 4 · Phase 3 7 · Phase 4 3
First in 2003; this study’s year is marked. 6 started in 2019.
This study's planned enrollment of 60 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 148 across the 21 interventional studies, 550 across the 4 observational. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 25 have an industry lead sponsor. The 10 most frequent:
Fujian Academy of Traditional Chinese Medicine is the lead sponsor of 4 studies on the registry; none are open to participants now.
Fujian Academy of Traditional Chinese Medicine has 3 studies filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Osteoporosis, Postmenopausal with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Osteoporosis is a common senile disease with a high incidence. The Chinese medicine differentiation treatment has small side effects and can be taken for a long time, which has certain advantages. This project adopts the experience of the person in charge of the project-Xulin Jiangu Granules and clinically collects patients with postmenopausal osteoporosis (kidney deficiency and blood stasis syndrome).
Randomized control method was used to observe the clinical efficacy of the treatment of postmenopausal osteoporosis (kidney deficiency and blood stasis syndrome) with jiujian jiangu granules, combined with the gene expression of bone metabolism markers BALP, PINP, TRACP and S-CTX, and RANK, RANKL and OPG Detection, compared with the control group of ossification trihydrate capsules, to explore the mechanism of the treatment of postmenopausal osteoporosis by the continued Xulin Jiangu granules, and lay the foundation for the development of new drugs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Xulin Jiangu granule 15g tablet by mouth every 6 hour for 6 months
Drug: Xulin Jiangu granules · Drug: Calcitriol capsules
Calcitriol capsules tablets 0.25 ug by mouth every 6 hour for 6 months
Drug: Xulin Jiangu granules · Drug: Calcitriol capsules
Xulin Jiangu granules tablets
Calcitriol capsules tablets
Bone density(BMD)
BMD is the gold standard of oeteoporosis
Time frame: Xulin Jiangu treats for up to six months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2019; primary completion for Sep 2021, 24 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Osteoporosis, Postmenopausal →
Fujian Academy of Traditional Chinese Medicine